by Jordana Choucair | Oct 12, 2021 | Life Sciences
A new Kaiser Family Foundation poll revealed that 83 percent of the public favors allowing the government to negotiate lower drug prices for Medicare and private insurance plans. Ninety-three percent of respondents agreed that even if the prices were lower drugmakers...
by Jordana Choucair | Oct 12, 2021 | Access & Coverage
The Justice Department asked a federal appeals court to reinstate a judge’s ruling that blocked Texas’s restrictive new abortion law while the case makes its way through the courts. The government argues that the ban on most abortions after about six weeks...
by Jordana Choucair | Oct 11, 2021 | Public Health/Prevention
Anthony Fauci said in a CNN interview that things are headed in the “right direction” as COVID-19 cases, hospitalizations, and deaths trend downward. However, he cautioned that people shouldn’t “just throw your hands up and say it’s all over” given that 68 million...
by Jordana Choucair | Oct 11, 2021 | Providers
Smaller hospitals, especially in rural areas, are struggling to comply with the hospital price transparency rule. While large systems have the means to work companies such as Epic Systems and Cerner to organize claims and prices, smaller hospitals have a harder time...
by Jordana Choucair | Oct 11, 2021 | Payers
The CMS released new data showing that nearly four times as many Medicare Advantage (MA) plans scored the highest quality rating possible for 2022 as compared with the year before. Seventy-four MA plans with prescription drug coverage earned five out of five stars, up...
by Jordana Choucair | Oct 11, 2021 | Life Sciences
Merck & Co. and partner Ridgeback Biotherapeutics LP said they asked the FDA to authorize their COVID-19 antiviral pill, which curbed hospitalizations and deaths in a late-stage study. According to Merck CEO Robert Davis, the “extraordinary impact of this pandemic...
Recent Comments